Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Thoracic 1

Conditions

Colorectal Neoplasms 25Pancreatic Neoplasms 19Neoplasm Metastasis 17Neuroblastoma 8Lung Neoplasms 6Rhabdomyosarcoma 5Rectal Neoplasms 5Neoplasms 5Esophageal Squamous Cell Carcinoma 5Colonic Neoplasms 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma, Ewing 4Sarcoma 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 4Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Biliary Tract Neoplasms 3Wilms Tumor 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Kidney Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Glioma 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Breast Neoplasms 2

Interventions

Bevacizumab 35Paclitaxel 31Carboplatin 24pembrolizumab 23Specimen Handling 21Magnetic Resonance Spectroscopy 19Gemcitabine 18olaparib 16liposomal doxorubicin 16Cyclophosphamide 15fludarabine 12Topotecan 12Biopsy 12niraparib 11Cisplatin 10Taxes 8Nivolumab 8Immunoglobulin G 8Fulvestrant 8Disulfides 8Doxorubicin 7aldesleukin 6Surveys and Questionnaires 6palbociclib 5Oxaliplatin 5Fluorouracil 5trastuzumab deruxtecan 4oregovomab 4mirvetuximab soravtansine 4X-Rays 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Irinotecan × 90 days × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04657068 2026-03-18

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Artios Pharma Ltd

Phase 1/2 Recruiting
442 enrolled
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Acinar Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡